POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
Reversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients.
COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
Though LHRH agonists may be the preferred method of ovarian function suppression, ovarian ablation is a viable option for select premenopausal breast cancer patients.
Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.
